ArriVent BioPharma (AVBP) Non-cash Items (2024 - 2026)

ArriVent BioPharma has disclosed Non-cash Items across 3 years of filings, most recently posting $40.1 million for Q1 2026.

• Non-cash Items for Q1 2026 came in at $40.1 million, up 35.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.1 million (up 35.65% YoY), and the FY2025 annual result was $1.5 million, up 107.4% from the prior year.
• Non-cash Items came in at $40.1 million for Q1 2026 at ArriVent BioPharma, up from $1.5 million in the prior quarter.
• In the past five years, Non-cash Items ranged from a high of $42.9 million in Q3 2024 to a low of $646440.0 in Q2 2024.
• The 3-year median for Non-cash Items is $28.5 million (2025), against an average of $19.8 million.
• Peak annual rise in Non-cash Items reached 107.4% in 2025, while the deepest fall reached 33.57% in 2025.
• ArriVent BioPharma's Non-cash Items stood at $724934.0 in 2024, then soared by 107.4% to $1.5 million in 2025, then jumped by 2563.79% to $40.1 million in 2026.
• The last three Non-cash Items figures came in at $40.1 million (Q1 2026), $1.5 million (Q4 2025), and $28.5 million (Q3 2025), per Business Quant data.